Literature DB >> 29632056

Trends in Incidence and Factors Affecting Survival of Patients With Cholangiocarcinoma in the United States.

Shiva Kumar R Mukkamalla1, Hussain M Naseri1, Byung M Kim1, Steven C Katz1, Vincent A Armenio1.   

Abstract

Background: Cholangiocarcinoma (CCA) includes cancers arising from the intrahepatic and extrahepatic bile ducts. The etiology and pathogenesis of CCA remain poorly understood. This is the first study investigating both incidence patterns of CCA from 1973 through 2012 and demographic, clinical, and treatment variables affecting survival of patients with CCA. Patients and
Methods: Using the SEER database, age-adjusted incidence rates were evaluated from 1973-2012 using SEER*Stat software. A retrospective cohort of 26,994 patients diagnosed with CCA from 1973-2008 was identified for survival analysis. Cox proportional hazards models were used to perform multivariate survival analysis.
Results: Overall incidence of CCA increased by 65% from 1973-2012. Extrahepatic CCA (ECC) remained more common than intrahepatic CCA (ICC), whereas the incidence rates for ICC increased by 350% compared with a 20% increase seen with ECC. Men belonging to non-African American and non-Caucasian ethnicities had the highest incidence rates of CCA. This trend persisted throughout the study period, although African Americans and Caucasians saw 50% and 59% increases in incidence rates, respectively, compared with a 9% increase among other races. Median overall survival (OS) was 8 months in patients with ECC compared with 4 months in those with ICC. Our survival analysis found Hispanic women to have the best 5-year survival outcome (P<.0001). OS diminished with age (P<.0001), and ECC had better survival outcomes compared with ICC (P<.0001). Patients who were married, were nonsmokers, belonged to a higher income class, and underwent surgery had better survival outcomes compared with others (P<.0001). Conclusions: This is the most up-to-date study of CCA from the SEER registry that shows temporal patterns of increasing incidence of CCA across different races, sexes, and ethnicities. We identified age, sex, race, marital status, income, smoking status, anatomic location of CCA, tumor grade, tumor stage, radiation, and surgery as independent prognostic factors for OS in patients with CCA.
Copyright © 2018 by the National Comprehensive Cancer Network.

Entities:  

Mesh:

Year:  2018        PMID: 29632056     DOI: 10.6004/jnccn.2017.7056

Source DB:  PubMed          Journal:  J Natl Compr Canc Netw        ISSN: 1540-1405            Impact factor:   11.908


  16 in total

1.  Prognostic Nomogram That Predicts Overall Survival of Patients with Distal Cholangiocarcinoma After Pancreatoduodenectomy.

Authors:  Qiao Chen; Jiayi Li; Bao Jin; Xiangan Wu; Yue Shi; Haifeng Xu; Yongchang Zheng; Yingyi Wang; Shunda Du; Xin Lu; Xinting Sang; Yilei Mao
Journal:  Cancer Manag Res       Date:  2020-10-20       Impact factor: 3.989

2.  Trends in surgery and disparities in receipt of surgery for intrahepatic cholangiocarcinoma in the US: 2005-2014.

Authors:  Eke Ransome; Li Tong; Jairo Espinosa; Jesse Chou; Vishal Somnay; Gitonga Munene
Journal:  J Gastrointest Oncol       Date:  2019-04

3.  A Phase II Study of Pembrolizumab in Combination with Capecitabine and Oxaliplatin with Molecular Profiling in Patients with Advanced Biliary Tract Carcinoma.

Authors:  Cecilia Monge; Erica C Pehrsson; Changqing Xie; Austin G Duffy; Donna Mabry; Bradford J Wood; David E Kleiner; Seth M Steinberg; William D Figg; Bernadette Redd; Anuradha Budhu; Sophie Wang; Mayank Tandon; Lichun Ma; Xin Wei Wang; Tim F Greten
Journal:  Oncologist       Date:  2022-03-11

4.  Cholangiocarcinoma in Pacific Islanders Compared to Asians.

Authors:  Jessica R Shiosaki; Tomoki Sempokuya; Brenda Y Hernandez; Linda L Wong
Journal:  Hawaii J Health Soc Welf       Date:  2021-02-01

5.  Attenuation of CD47-SIRPα Signal in Cholangiocarcinoma Potentiates Tumor-Associated Macrophage-Mediated Phagocytosis and Suppresses Intrahepatic Metastasis.

Authors:  Kulthida Vaeteewoottacharn; Ryusho Kariya; Phattarin Pothipan; Sawako Fujikawa; Chawalit Pairojkul; Sakda Waraasawapati; Kazuhiko Kuwahara; Chaisiri Wongkham; Sopit Wongkham; Seiji Okada
Journal:  Transl Oncol       Date:  2018-11-09       Impact factor: 4.243

6.  Preoperative Bilirubin-Adjusted Carbohydrate Antigen 19-9 as a Prognostic Factor for Extrahepatic Cholangiocarcinoma Patients at a Single Center.

Authors:  Jiayi Li; Qiao Chen; Bao Jin; Yue Shi; Xiangan Wu; Haifeng Xu; Yongchang Zheng; Yingyi Wang; Shunda Du; Xin Lu; Yilei Mao; Xinting Sang
Journal:  Cancer Manag Res       Date:  2020-01-20       Impact factor: 3.989

7.  Complete Pathological Response to Neoadjuvant Chemoimmunotherapy in a Patient With Metastatic Intrahepatic Cholangiocarcinoma With High Tumor Mutational Burden.

Authors:  Mohammad Abudalou; Eduardo A Vega; Svetlana Kondratiev; Claudius Conrad; Olga Kozyreva
Journal:  Cureus       Date:  2021-12-05

8.  Risk factors, epidemiology and prognosis of cholangiocarcinoma in Finland.

Authors:  Nina Barner-Rasmussen; Eero Pukkala; Kishor Hadkhale; Martti Färkkilä
Journal:  United European Gastroenterol J       Date:  2021-09-17       Impact factor: 4.623

9.  The Impact of a History of Different Other Cancers on the Long-Term Outcomes of Patients with Intrahepatic Cholangiocarcinoma: A Population-Based Analysis.

Authors:  Jiawei Chai; Junjie Kong; Kunbing Zhu
Journal:  Biomed Res Int       Date:  2022-02-25       Impact factor: 3.411

Review 10.  Systemic treatment options for advanced biliary tract carcinoma.

Authors:  Changqing Xie; Nicole A McGrath; Cecilia Monge Bonilla; Jianyang Fu
Journal:  J Gastroenterol       Date:  2020-08-03       Impact factor: 7.527

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.